EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intra‐striatal infusion of the small molecule alpha‐synuclein aggregator, FN075, does not enhance parkinsonism in a subclinical AAV‐alpha‐synuclein rat model

Tommy Patton iD, Giulia Comini, Kaushik Narasimhan, Andrew G Cairns, Jörgen Ådén, Fredrik Almqvist, Alexis Bemelmans, Emmanuel Brouillet, Declan P McKernan iD, Eilís Dowd iD

European Journal of Neuroscience · 2024

DOI: 10.1111/ejn.16493 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neuroscience, 2024. Verfasst von Tommy Patton und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology & Therapeutics and Galway Neuroscience Centre, University of Galway, Galway, Ireland. Hauptthemen laut MEDLINE: alpha-Synuclein, Dependovirus, Corpus Striatum. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Galway Hardiman Scholarship, Science Foundation Ireland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Numerous challenges hinder the development of neuroprotective treatments for Parkinson's disease, with a regularly identified issue being the lack of clinically relevant animal models. Viral vector overexpression of α‐synuclein is widely considered the most relevant model; however, this has been limited by high variability and inconsistency. One potential method of optimisation is pairing it with a secondary insult such as FN075, a synthetic molecule demonstrated to accelerate α‐synucleinopathy. Thus, the aim of this study was to investigate if sequential infusion of adeno‐associated virus (AAV)‐α‐synuclein and FN075 into the rat brain can replicate α‐synucleinopathy, nigrostriatal pathology and motor dysfunction associated with Parkinson's disease. Rats received a unilateral injection of AAV‐α‐synuclein (or AAV‐green fluorescent protein) into two sites in the substantia nigra, followed 4 weeks later by unilateral injection of FN075 (or vehicle) into the striatum. Animals underwent behavioural testing every 4 weeks until sacrifice at 20 weeks, followed by immunohistochemistry assessment post‐mortem. As anticipated, AAV‐α‐synuclein led to extensive overexpression of human α‐synuclein throughout the nigrostriatal pathway, as well as elevated levels of phosphorylated and aggregated forms of the protein. However, the sequential administration of FN075 into the striatum did not exacerbate any of the α‐synuclein pathology. Furthermore, despite the extensive α‐synuclein pathology, neither administration of AAV‐α‐synuclein nor FN075, alone or in combination, was sufficient to induce dopaminergic degeneration or motor deficits. In conclusion, this approach did not replicate the key characteristics of Parkinson's disease, and further studies are required to create more representational models for testing of novel compounds and treatments for Parkinson's disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-SynucleinDependovirusCorpus StriatumAnimalsRatsMaleDisease Models, AnimalParkinsonian DisordersRats, Sprague-DawleyGenetic VectorsSubstantia NigraHumans

Stichwörter der Autor:innen

AAVFN075Parkinson'sadeno‐associated virusalpha‐synuclein

Substanzen

alpha-Synuclein

Autor:innen und Institutionen

  • Pharmacology & Therapeutics and Galway Neuroscience Centre, University of Galway, Galway, Ireland.
  • Department of Chemistry, Umeå University, Umeå, Sweden.
  • Université Paris-Saclay, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Centre National de la Recherche Scientifique (CNRS), Molecular Imaging Research Center (MIRCen), Laboratoire des Maladies Ne…

ORCID-Profile: Tommy Patton, Declan P McKernan, Eilís Dowd

Förderung

  • University of Galway Hardiman Scholarship
  • Science Foundation Ireland

Zitieren

APA

Patton, T., Comini, G., Narasimhan, K., Cairns, A. G., Ådén, J., Almqvist, F., Bemelmans, A., Brouillet, E., McKernan, D. P., & Dowd, E. (2024). Intra‐striatal infusion of the small molecule alpha‐synuclein aggregator, FN075, does not enhance parkinsonism in a subclinical AAV‐alpha‐synuclein rat model. European Journal of Neuroscience. https://doi.org/10.1111/ejn.16493

Vancouver

Patton T, Comini G, Narasimhan K, Cairns AG, Ådén J, Almqvist F, et al. Intra‐striatal infusion of the small molecule alpha‐synuclein aggregator, FN075, does not enhance parkinsonism in a subclinical AAV‐alpha‐synuclein rat model. European Journal of Neuroscience. 2024. doi:10.1111/ejn.16493

BibTeX
@article{Patton2024,
  author = {Patton, Tommy and Comini, Giulia and Narasimhan, Kaushik and Cairns, Andrew G and Ådén, Jörgen and Almqvist, Fredrik and Bemelmans, Alexis and Brouillet, Emmanuel and McKernan, Declan P and Dowd, Eilís},
  title = {Intra‐striatal infusion of the small molecule alpha‐synuclein aggregator, FN075, does not enhance parkinsonism in a subclinical AAV‐alpha‐synuclein rat model},
  journal = {European Journal of Neuroscience},
  year = {2024},
  doi = {10.1111/ejn.16493}
}
Kostenlos starten →